Bioprocessing Revisited: Applying The Lessons From mAbs Production To Advanced Therapeutics Manufacturing

Biotherapeutic manufacturers are increasingly recognizing the need to evolve beyond traditional batch and fed-batch processing methods. To meet the growing demand for advanced therapies, there is a pressing need to adopt continuous manufacturing approaches that can significantly enhance dose production, reduce manufacturing costs, and ensure consistent product quality. In this webinar hosted by Repligen, industry leaders will delve into how the bioprocessing innovations pioneered in monoclonal antibody (mAb) production can be effectively translated to the manufacturing of advanced therapeutic medicinal products (ATMPs). These include gene therapies, cell therapies, nucleic acid-based treatments, oncolytic viruses, vaccines, and exosomes.

The discussion highlights transformative technologies that are currently driving efficiency in both mAb and vector-based therapeutic production. Discover how these innovations are not only streamlining workflows but also enabling higher productivity, scalability, and cost-effectiveness.